



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

BS

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,277	02/13/2001	Dominique Therese Marie Frechon	P66034US0	5117
136	7590	06/21/2005	EXAMINER	
JACOBSON HOLMAN PLLC 400 SEVENTH STREET N.W. SUITE 600 WASHINGTON, DC 20004			DUFFY, PATRICIA ANN	
			ART UNIT	PAPER NUMBER
			1645	

DATE MAILED: 06/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/674,277	FRECHON ET AL.
	Examiner	Art Unit
	Patricia A. Duffy	1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 27 December 2004.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 20-25 and 27-60 is/are pending in the application.
4a) Of the above claim(s) 31-60 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 20-25 and 27-30 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
5) Notice of Informal Patent Application (PTO-152)
6) Other: *sequence attachments*.

RESPONSE TO AMENDMENT

The amendments to the claims filed on 5-12-04 and 12-27-04 have been entered into the record. The amendment to the specification filed on 7-12-04 has been entered into the record. The responses filed 5-12-04, 7-12-04 and 12-27-04 have been entered into the record. Claims 1-19 and 26 have been cancelled. Claims 20-25, and 27-60 are pending.

The text of Title 35 of the U.S. Code not reiterated herein can be found in the previous office action.

Election/Restrictions

Upon reconsideration of the lack of unity, and the fact that the individual SEQ ID NOS: 1 and 2 were examined in the first office action on the merits, Groups I -III are hereby rejoined. The lack of unity with respect to the corresponding method claims and primer pairs is maintained in view that these lack unity of invention in light of the art maintained. The traversal is on the ground(s) that the cited reference no longer anticipates claim 20 and as such, the claims now have unity of invention. This is not found persuasive because the deletion of "insertion" does not remove the art because "mutation" or "substitution" as it is still recited in the claims, broadly encompasses substitutions, insertions and deletions. Substitutions base X could be X for X+1, 2, 3... resulting in a substitution of a single base for multiple replacements or substitution of bases XYZ could be substituted with XZ resulting in the loss of a single or multiple bases and the "consisting of language" does not limit the claims to shorter fragments because a nucleic acid that is larger can also specifically detect and hybridize. Therefore, claims 20-25, 27-30 are under examination. Claims 31-60 are withdrawn to inventions that lack unity of invention for reasons made of record.

The requirement is still deemed proper and is therefore made FINAL.

Rejections Withdrawn

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

Rejections Maintained

Claims 20 and 21 stand rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention is maintained for reasons made of record for claim 1.

The amendment to the claims does not moot the rejection. As previously made of record, *Vas-Cath Inc. v. Mahurkar*, 19 USPQ2d 1111, 1117, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, *as of the filing date sought*, he or she was in possession of the claimed invention". "The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed* [emphasis added]". Therefore, Applicants' arguments are not persuasive. SEQ ID NO: 1 and 2 fragments of the p0157 plasmid of the prior art. No written description is provided in the specification for any other species of nucleic acids that are derived therefrom by mutation, deletion and/or substitution with the claimed function of specifically detecting enterohemorrhagic E. coli. The disclosure of a these discrete sequences (*which the claims are not limited toward*) does not reasonably constitute the claimed genus of nucleic hybridizing nucleic acids that are mutated, deleted or substituted in one or more bases. Analogous to the situation decided in *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993), "an adequate written description of a DNA [product] requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself". *Fiddes v. Baird*, 30 USPQ2d 1481, 1483 (1993) held that claims directed to mammalian FGFs were found unpatentable due to lack of written

description for the broad class, in which the specification had provided an adequate description of only the bovine sequence. Accordingly, the court held in *Univ. California v. Eli Lilly and Co.*, 43 USPQ2d 1398 (Fed. Cir. 1997) that: "One skilled in the art therefore cannot, as one can do with a fully described genus, visualize or recognize the identity of the members of the genus. A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the gene does, rather than what it is" and that: "A description of a genus of cDNAs [products] may be achieved by means of a recitation of a representative number of cDNAs [products], *defined by nucleotide sequence*, failing in the scope of the genus or of a recitation of structural features common to the members of the genus, *which features constitute a substantial portion of the genus* [emphasis added]. This is analogous to enablement of a genus under 112, [first paragraph], by showing the enablement of a representative number of species within the genus. See *Angstadt*, 537 F.2d at 502-03, 190 USPQ at 218". The specification does not teach any subsequence of either SEQ ID NO:1 or 2, that was derived by mutation, deletion and/or substitution of one or more bases. There is no written description for any sequences derived, much less those that would hybridize.

The rejection is maintained over the claimed sequences as "derived from SEQ ID NO:1 or 2 by mutation, deletion and/or substitution of one or more bases".

Claims 20, 21 and dependent claims 22-25 stand rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is maintained for reasons made of record for the previous claims.

Applicants' arguments have been carefully considered. Applicants argue that representative examples of such high stringency conditions are recited in the specificaiton. This is not persuasive, exemplification is not a definition of specific conditions and limitations as recited in the specification are not read into the claims.

Art Unit: 1645

Further, the conditions relied upon at page 7, lines 19-30 are admittedly specifically related to the specific chemical structure of the hybridizing nucleic acid, the structure of which is not defined in the claims. The rejection is therefore maintained.

Claims 20, 21, 22 and 24 stand rejected under 35 U.S.C. 102(b) as being clearly anticipated by Brunder et al (Microbiology, 146:3305-3315, 1996) for reasons made of record in the Office Action Mailed 12-13-03.

Applicants' arguments have been carefully considered but are not persuasive. Applicants argue that the inventors have demonstrated that *E. coli* 0157:H7 is characterized by the stable integration of a portion of the *IS91* sequence into the *katP* gene. According to the stable combination of a portion of *IS91* with a portion of *katP* is a specific marker for *E. coli* 0157:H7 strains. This is not persuasive, the claims are not so limited because "a portion" is a single "nucleotide" and the claims specifically encompass mutation, deletion or substitution of one or more bases or different ones and that the sequence of the prior art does not detect other EHEC's as set forth in the claims. The specific junction relied upon as set forth in the Figure is not defined in claim 21 and neither is the "portion" of sequence of *IS91* or "portion" of gene sequence of *katP*. Additionally, the "substitution could represent the substitution of "X" for "X + 12 or more additional bases". Further, plasmid pSm10 or pSM9 comprises the *Sma*-1 fragment of pO157 and contains more than 1 Kb upstream of the beginning of *katP* (see page 3307, Figure 1) as derived from which would specifically hybridize to SEQ ID NO:1, because as with SEQ ID NO:1 is derived from the O157 enterohemorrhagic plasmid of the prior art. Further, the *Sma*-1 fragment inherently has the claimed nucleotide residues of claim 22. It is also noted that the first *Hind*III fragment of the *Sma*-1 fragment of pSm10 or pSmK9 as disclosed by Brunder et al would also inherently hybridize under the high stringency conditions and would be specific for the sequence that they were derived from. The specifically claimed nucleotide sequence is inherent to the plasmids. The art is applied

Art Unit: 1645

against the nucleic acids of claims 24 and 25 because the claims are confusing as dependent from claims 20 and 21 respectively for reasons set forth in the second paragraph rejection above.

Claims 20, 21, 22, 24 and 25 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Makino et al , (DNA Research, 5(1):1-9, Feb 28, 1998) in light of GenEMBL Accession Number AB011549.

Makino et al teach the isolation of and complete nucleotide sequences of 93 kb and 3.3 kb plasmids of an enterohemorrhagic *Escherichia coli* 0157:H7 derived from Sakai outbreak. Makino et al teach extraction of DNA from the bacterium and isolation of the pO157 plasmid and subsequent sequencing of the plasmid, see page 2, Materials and Methods. Makino et al teach that pO157 is represented by EMBL Accession Number AB011549 (page 2, column 2, second full paragraph). The isolated plasmid inherently characterized by the stable integration of a portion of the *IS91* sequence into the *katP* gene and inherently hybridizes under the asserted conditions because it is 99.2% identical as compared to SEQ ID NO:1 (see attached alignment). As previously set forth, the language of mutation, deletion and/or substitution of one or more bases specifically includes the differences between SEQ ID NO:1 and the plasmid of the art. The deletion of "insertion" does not remove the art because "mutation" or "substitution" as it is still recited in the claims, broadly encompasses substitutions, insertions and deletions. Mutations include deletions and substitutions base X could be X for X+1, 2, 3 nts... resulting in a substitution of a single base for multiple replacements or substitution of bases XYZ could be substituted with XZ resulting in the loss or addition of a single or multiple bases and the "consisting of language" does not limit the claims to shorter fragments because a nucleic acid that is larger can also specifically detect and hybridize. The isolated plasmid inherently hybridizes under stringent conditions because it comprises a sequence that is 98.7% identical as compared to SEQ ID NO:2 as evidenced by GenEMBL

Art Unit: 1645

Accession Number AB011549 (see attached alignment). Applicants argue that the sequence was not available prior to the priority date of this application. This is not persuasive, the filing date of the instant specification in the US is the instant filing date and the filing date of the international application is 4-27-1999. Applicants the priority document of 99/05329 filed 4-28-98 is in a foreign language and such the priority is not perfected. Even if the foreign priority is perfected, the paper was available as of February 29, 1998 and fully enabled as of this date. The nucleic acid sequence is inherent to the isolated plasmid. Claimed residues 400-407 of SEQ ID NO:1, SEQ ID NOS: 10-13, 18-20, 21-23 and 25 are inherently contained in the hybridizing plasmid of the prior art (see attached alignments for SEQ ID NOS:1 and 2).

New Rejections Based on Amendment

The amendment filed 7-12-04 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: Applicants indicate a correction to the specification based on a foreign patent document of French origin. It is noted where a foreign priority document under 35 U.S.C. 119 is of record in the U.S. application file, applicant may not rely on the disclosure of that document to support correction of an error in the pending U.S. application. *Ex parte Bondiou*, 132 USPQ 356 (Bd. App. 1961). This prohibition applies regardless of the language of the foreign priority documents because a claim for priority is simply a claim for the benefit of an earlier filing date for subject matter that is common to two or more applications, and does not serve to incorporate the content of the priority document in the application in which the claim for priority is made. This prohibition does not apply where the U.S. application explicitly incorporates the foreign priority document by reference. Applicants have not provided for a specific incorporation by references in the originally filed transmittal documents or

in the first line of the specification. As such, reliance on an incorporation by reference to correct the error is impermissible in this situation. Where a U.S. application as originally filed was in a non-English language and an English translation thereof was subsequently submitted pursuant to 37 CFR 1.52(d), if there is an error in the English translation, applicant may rely on the disclosure of the originally filed non-English language U.S. application to support correction of an error in the English translation document. In this case the originally filed document was not filed in a non-English language. Applicants are directed to MPEP section 2163.07 for correcting "obvious errors" not based on the priority documents.

Claims 20-25 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

The claims now require the nucleic acid to "specifically detect" enterohemorrhagic *E. coli* wherein it is a fragment or derived from SEQ ID NO:1 that specifically detects enterohemorrhagic *E. coli* (EHECs) wherein the fragment or derived sequence contains a nucleotide sequence of SEQ ID NO:1 resulting from a stable combination of at least a portion of insertion sequence IS91 and at least a portion of gene sequence KatP. It is noted that the specification teaches that this portion 400-407 is *specific to O157:H7* and does not detect other EHEC's (see page 5, lines 12-20) as it relates to claims 21, 22, 24 (SEQ ID NOS:12, 13, 18, 19 and 20). As such, the use of this junction that is specifically described in the specification as unique to O157:H7, as an attribute of ECECs in general is considered new matter because the specification specifically teaches that it is not a genus marker.

Art Unit: 1645

Claims 20-25 and 27-30 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

With respect to claims 20-25, the claims now recite that the isolated nucleic acid "specifically detect" enterohemorrhagic *Escherichia coli* (EHECs). In the absence of any definition in the specification, this phrase has been interpreted for this rejection as *exclusive detection of the target* (i.e. EHECs) to rule out detection of *all others*. The specification fails to disclose any individual/single isolated nucleic acid that specifically detects EHECs and some of the recited isolated nucleic acids are present in other genomes that are not EHEC's and an isolated nucleic acid consisting of SEQ ID NOS:10-13, 18-27 *per se* are of apparently insufficient length to form a stable hybrid under conditions such that they could *detect only EHECs* using single nucleic acid detection method such as hybridization. The specification is devoid of written description of specificity analysis with single nucleic acid probes for any of the particularly claimed nucleic acids. For example, with respect to specificity of detection using a single nucleic acid, residues 400-407 of SEQ ID NO:1 are present in fungi (see attached alignment); SEQ ID NO:19 is present in *Pseudomonas syringae* DNA for IS801 insertion sequence (see attached alignment) and SEQ ID NO:18 is present in *Salmonella paratyphi A* (see attached alignment) and porcine liver factor XII (see attached alignment) and therefore these nucleic acids are not specific as claimed and one would have reason to doubt the asserted truth that the others as specifically claimed are able to "specifically detect" detect EHECs as claimed. In the absence of further guidance from Applicants as to which single nucleic acids "specifically detect EHECs" as compared to other microorganism under which hybridization or other conditions. The primer pairs do not support the specific detection using a single nucleic acid. Primer pairs amplify a fragment that is specific and they

themselves do not necessarily have to be exclusive. Therefore, the use of a specific primer pair to amplify a nucleic acid to generate a third nucleic acid sequence that has been identified as specific to 0157 is specifically distinguished from that which is claimed herein.

With respect to claims 27-30, Applicant's referral to the deposit of the clones pDF3 and pDF4 on page 5 of the specification is an insufficient assurance that all required deposits have been made and all the conditions of 37 CFR §1.801-1.809 have been met. If the deposit has been made under the provisions of the Budapest Treaty, filing of an affidavit or declaration by applicant or assignees or a statement by an attorney of record who has authority and control over the conditions of deposit over his or her signature and registration number stating that the deposit has been accepted by an International Depository Authority under the provisions of the Budapest Treaty, that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application and that the deposit will be replaced if viable samples cannot be dispensed by the depository is required. This requirement is necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State. *Amendment of the specification to recite the date of deposit and the complete name and full street address of the depository is required.* If the deposits have not been made under the provisions of the Budapest Treaty, then in order to certify that the deposits comply with the criteria set forth in 37 CFR §1.801-1.809, assurances regarding availability and permanency of deposits are required. Applicant's attention is directed to In re Lundack, 773 F.2d. 1216, 227 USPQ 90 (CAFC 1985) and 37 CFR §1.801-1.809 for further information concerning deposit practice.

Claims 20, 21 and dependent claims 22-25 stand rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims now recite that the isolated nucleic acid "specifically detects" however, specificity is not defined in the specification nor is it defined as exclusive binding and therefore the metes and bounds of the claims can not be ascertained.

As to claims 22-25, the claims recite "the nucleic acid according to claim X" and it is not clear if the claims are intended to reference the "fragment" or "derived sequence". As such, it is not clear what alternative is specifically being limited in the dependent claims and therefore the dependent claims do not have proper antecedent basis or are properly dependent from independent claims 20 or 21.

As to claim 24, SEQ ID NOS:10 and 11, these sequences do not apparently have "at least a portion of IS91 and at least a portion of gene sequence katP, which appears to bridge residues 406-407 of SEQ ID NO:1 (see Figure 1). This issue is best resolved by Applicants pointing to the corresponding residues of each of these sequences that correspond to "the claimed "at least a portion of insertion sequence IS91" and "at least a portion of gene sequence katP".

Claims 20-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Makino et al , (DNA Research, 5(1):1-9, Feb 28, 1998) in view of Schmidt et al, Microbiology 142(4):907-914, 1996 and Kennell et al 1971("Principles and properties of nucleic acid hybridization", Progr. Nucl. Acid Res. Mol. Biol. 11: 259-301) in light of GenEMBL Accession Number AB011549 .

Makino et al is set forth *supra*. Makino et al differs by not teaching fragments of SEQ ID NO:1 or SEQ ID NO:2. Kennel et al teach the location of the open reading frames in the sequenced p0157 plasmid, including the hly operon. Makino et al identifies

the open reading frames of the junction of IS91/katP by nucleotide number and another open reading frame 82 corresponding to residues 87658-88761.

Schmidt et al teach that circular restriction fragment map of wild-type plasmid p0517 and location of the EHEC-hly operon (see page 910, Figure 2 and Table 1).

Kennell et al teach that nucleic acid sequences having a minimum size for stable complex formation is from 10-20 nucleotides depending upon the G+C content (see paragraph bridging pages 260-261).

It would have been *prima facie* obvious one of ordinary skill in the art at the time that the invention was made to use any restriction fragment of the p0157 plasmid of Schmidt et al of at least 10-20 nucleotides in length as a probe or primer to detect the p0157 of Makino et al or open reading fragment thereof because Makino et al teach that *E. coli* 0157:H7 is a pathogen that causes bloody diarrhea and hemorrhagic colitis and Kennel et al teach that the nucleic acids would form stable hybrids. To restate, any fragment of the p0157 plasmid from *E. coli* 0157:H7 having at least 10-20 nucleotides in length is *prima facie* obvious as a probe/primer for detecting the sequence of origin from enterohemorrhagic *E. coli* 0157:H7. The restriction fragment(s) would specifically detect the sequence from which it was derived. The art is applied against the nucleic acids of claims 24 and 25 because the claims are confusing as dependent from claims 20 and 21 respectively for reasons set forth in the second paragraph rejection above.

Status of Claims

All claims stand rejected.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP

Art Unit: 1645


§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia A. Duffy whose telephone number is 571-272-0855. The examiner can generally be reached on M-Th 6:30 am - 6:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on 571-272-0864.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.


Patricia A. Duffy

Application/Control Number: 09/674,277

Page 14

Art Unit: 1645

Primary Examiner

Art Unit 1645

QY	240	CGGGCTGATACGGCAGATAGGTGGCAAAACTCCGGTCCGGAGGGCTATTTCAG	299	Db	8156	GGGGCATACATTGGTAAGCACATTCGCTGCGCTTCCTGAAATAATGATGGCGCA	8215
Db	7076	CGCGCTGATACGGCAGATAGGTGGCAAAACTCCGGTCCGGAGGGCTATTTCAG	7135	QY	1380	GGGGCTGATGGGACCTGGGAGGAGGACTGGGATGGAAATAATGGTGTCA	1439
Db	300	GATACCCCTCGTCATACAGCTGAAACCGAGAACGACCGGTTTGTGATGCCA	359	Db	8216	GGGGCTGATGGGACCTGGGAGGAGGACTGGGATGGAAATAATGGTGTCA	8275
Qy	7136	GATACCCCTCGTCATACAGCTGAAACCGAGAACGACCGGTTTGTGATGCCA	7195	QY	1440	GGAAACGGGAAATAACATACCATCACAGTGGGCTGGGAGGGCTGGCGAC	1489
Db	360	CGAAGGGGAAATACTAGGTCTGGAGGACTCAAGGCCATGTCGGGTTGGA	419	Db	8276	GGAAACGGGAAATAACATCACAGTGGGCTGGGAGGGCTGGCGAC	8325
Qy	7196	CGAAGGGGAAATACTAGGTCTGGAGGACTCAAGGCCATGTCGGGTTGGA	7255				
QY	420	ACCCCTAGTATTTGTCGTTAGTATCTCCAGCAATAAGGTTATCTGTGCACT	479				
Db	7256	ACCCCTAGTATTTGTCGTTAGTATCTCCAGCAATAAGGTTATCTGTGCACT	7315				
Qy	480	AATAAAGTGACTTTGTATACATGCAATTCCCTTAATCCGGAGTATTCTGATG	539				
Db	7316	AATAAAGTGACTTTGTATACATGCAATTCCCTTAATCCGGAGTATTCTGATG	7375				
QY	540	ATAAAAGAACCTTCTGTCATCTTCGGCTATGGGAGCTTCTACCGCT	599				
Db	7376	ATAAAAGAACCTTCTGTCATCTTCGGCTATGGGAGCTTCTACCGCT	7435				
Qy	600	GTACCGCTGATAAAAGACTCAAATTCATCATCATCAGAACACTGATTAAC	659				
Db	7436	GTACCGCTGATAAAAGACTCAAATTCATCATCATCAGAACACTGATTAAC	7495				
Qy	660	CCCTGAGATTAACAGCCCTGAAATCAATCCCTGGGGCTGATTTGATGCCAC	719				
Db	7496	CCCTGAGATTAACAGCCCTGAAATCAATCCCTGGGGCTGATTTGATGCCAC	7555				
Qy	720	AGATTCAAGCTGGATATGGGCTCTAAAGATACTCAAGATTGCTGACACT	779				
Db	7556	AGATTCAAGCTGGATATGGGCTCTAAAGATACTCAAGATTGCTGACACT	7615				
QY	780	TCCAGGATTGGCTGCCCTGGATTATGGCTATGGCTTCTTATCTGCT	839				
Db	7616	TCCAGGATTGGCTGCCCTGGATTATGGCTATGGCTTCTTATCTGCT	7675				
Qy	840	TGGCACGGTGGCCGAAACATACAGGACATATGATEGCCGGAGGCCGTGCTAG	899				
Db	7676	TGGCACGGTGGCCGAAACATACAGGACATATGATEGCCGGAGGCCGTGCTAG	7735				
QY	900	CAACGTTTGAACCCCTGAACGGCTGGGATTAACGTTTATCTGGATAAAGCCGGCA	959				
Db	7736	CAACGTTTGAACCCCTGAACGGCTGGGATTAACGTTTATCTGGATAAAGCCGGCA	7795				
Qy	960	TTGGCTGGCCGGTCAAGAAAATACGGCTCCGATATTCCTGGGAGCCCTGATGTC	1019				
Db	7796	TTGGCTGGCCGGTCAAGAAAATACGGCTCCGATATTCCTGGGAGCCCTGATGTC	7855				
Qy	1020	CTGACTGTGTAATGCTGCCCTGAAATCTGGGATTAAGCTGGGATTTGCTGGGCA	1079				
Db	7856	CTGACTGTGTAATGCTGCCCTGAAATCTGGGATTAAGCTGGGATTTGCTGGGCA	7915				
Qy	1080	AGAGACATGACTGGGAGCTGGGACCTGGGCTGATGACAAACCCCTGGCA	1139				
Db	7916	AGAGACATGACTGGGAGCTGGGACCTGGGCTGATGACAAACCCCTGGCA	7975				
Qy	1140	GATAACGGATAAAACGGAAACCTGAGCCACGGCATGGGACTT	1199				
Db	7976	GATAACGGATAAAACGGAAACCTGAGCCACGGCATGGGACTT	8035				
Qy	1200	ATTATTCGCAATCTGAGGCCGGTGAACAGATGGGAAAGAT	1259				
Db	8036	ATTATTCGCAATCTGAGGCCGGTGAACAGATGGGAAAGAT	8095				
Qy	1250	ATCAGGAGGCTTTCACTGATGGATGAGACTGGGCTCTGATGCG	1319				
Db	8096	ATCAGGAGGCTTTCACTGATGGATGAGACTGGGCTCTGATGCG	8155				
	1320	GGGGGATACATTGGTAAGCACATGGCAAGCTCTCTGAAATAATGATGGCGCA	1379				

RESULT 5
LOCUS AB011549 92721 bp DNA circular BCT 27-APR-1999
DEFINITION Escherichia coli plasmid pO157 DNA, complete sequence.
ACCESSION AB011549
VERSION 1
KEYWORDS ToxR-regulated lipoprotein; tagA.
SOURCE Escherichia coli
ORGANISM Escherichia coli; Gammaproteobacteria; Enterobacteriales;
Enterobacteriaceae; Escherichia.
1 (sites)
REFERENCE Makino, K., Ishii, K., Yasunaga, T., Hattori, M., Yokoyama, K.,
Yutsudo, H. C., Kubota, Y., Yamada, T., Iida, T., Yamamoto, K.,
Honda, T., Han, C. G., Otsubo, E., Kasamatsu, M., Hayashi, T.,
and Shiragawa, H.
TITLE Complete nucleotide sequences of 93-kb and 3.3-kb plasmids of an
enterohemorrhagic Escherichia coli O157:H7 derived from Sakai
outbreak
JOURNAL DNA Res. 5 (1), 1-9 (1998)
PUBMED 9820540
REFERENCE 2 (bases 1 to 92721)
AUTHORS Makino, K.
TITLE Direct Submission
JOURNAL Submitted (24-FEB-1998) Kozo Makino, Research Institute for
Microbial Diseases, Osaka University, Molecular Microbiology;
Yamadaoka, 3-1, Suita, Osaka 562, Japan
(E-mail: makino@biken01.biken.osaka.ac.jp, Tel: 81-6-879-8318,
Fax: 81-6-879-8320)
COMMENT On Apr 20, 1999 this sequence version replaced gi:33336997.
FEATURES Location/Qualifiers
source
1. 92721
/organism="Escherichia coli"
/mol type="genomic DNA"
/strain="O157:H7"
/db Xref="RIMD 0509952"
/plasmid="pO157"
/note="RIMD 0509952 is a strain of enterohemorrhagic E. coli. EHBC O157:H7"
/join(92527..92721,1..2502)
/join(92527..92721,1..2502)
/gene="tagA"
/codon_start=1
/transl_table=11
/product="ToxR-regulated lipoprotein"
/protein_id="BA61175..3"
/db Xref="GI: 466329..3"
/translation="MNTKMMNEWRTPMKLKYLSCSTIILAPPAGVFSATAADNSAAYF
NTSQPIINDQSLIATLWTPSSLLPDITYLQCPDDEKMRVPESSGYSSTV
KLSDAAGSSSIHSHTNNVALEWHTANGRMWDRDYLQCPDDEKMRVPESS
IYGDKNVSLRNDIKIGAGCAGLHIDGMLTIPDRDFAKOEAEKREYFQCPVSR
MIVNNYAPHLKEVMLPQGELLTDMDPQNGWHSQGKTRQRGLVSGIGLDNANGLN
STAGLGENSHPTVAQLLAHNSPQVQDGRFIPNEYPSQTNEKSLCQNNOCQEPF
NYGLIGHYDQKGSFSPSIAANRFTMYPNSAIIORFENKAVDPSRSSTGFSKWNADT
DGKFGEDMAGGSPFSAIIRFENKAVDPSRSSTGFSKWNADT
QEMPEYHTIDRAEQITASVNELESKRMELMAEYAVVYHMMNGWNTTINYIPTASA

gene	11473... .12323
Query Match	98.7%
Exact Local Similarity	99.7%
Matches 1168; Conservative	0
11 TGGAAAAAGGCCAAATAA	
88939 TGGAAAAAGGCCAAATAA	
71 TGTCTGCGGTATTAA	
88879 TGTCTGCGGTATTAA	
131 CTCCGTTACGGAAAAACGCC	
88819 CTCCGTTACGGAAAAACCC	
251 ATCAAACCGGACTCAATA	
88699 ATCAAACCGGACTCAATA	
311 TCGGATAAAAAATCGGCCA	
88639 TCGGATAAAAAATCGGCCA	
371 CGTCCCTGTGACATTCTCT	
88579 CGTCCCTGTGACATTCTCT	
431 CGGAGCGGGAGACTGAGC	
88519 GGGAGCGGGAGACTGAGC	
491 CATGACCACCAACTGGCAA	
88459 CATGACCACCAACTGGCAA	
551 TAACATCTCGCTCATTC	
88399 TAACATCTCGCTCATTC	
611 TTACGCCGCCGCCACCA	
88339 TTACGCCGCCGCCACCA	
671 CAATACACGGACATAAATT	
88279 CAATACACGGACATAAATT	
731 AAGCGAACTTGTGCTGCG	
88219 AAGCGAACTTGTGCTGCG	
791 GGCTCAATTGCAATGCC	
88159 GGCTCAATTGCAATGCC	
851 GACACCTTCGCCATCGAT	
88099 GACACCTTCGCCATCGAT	
911 CAGATAATTCTGGAAAAACC	
88039 CAGATAATTCTGGAAAAACC	
971 ACTGAAAGCGGTGACCACTAT	
8779 ACTGAAAGCGGTGACCACTAT	

Qy	1031	ATGGCAGATGACCAAGATCAGGTTAAATCCCCGATAATCGTGAAGTCGAGGATGGA	1090	4.91	CATGACACCAACTGGCATCCGGTAACTCCGGTAAACGCTGGAAAGGSCACCTGGCCAT	550	
Db	87919	ATGGCAGATGACCAAGATCAGGTTAAATCCCCGATAATCGTGAAGTCGAGGATGGA	87860	88459	CATGACACCAACTGGCATCCGGTAAACGCTGGAAAGGSCACCTGGCCAT	88400	
Qy	1091	AGGAAAGGTGAAGGCTGTTCTGAAAGGATAAAGTGAATCGCCCTTTTCGTC	1150	551	TAACACATCCTGGCATTCAGGTTCTGCTGCTGCTGAGCGAGAAGGCTTCGATTTC	610	
Db	87859	AGGAAAGGTGAAGGCTGTTCTGAAAGGATAAAGTGAATCGCCCTTTTCGTC	87800	88399	TAACACATCCTGGCATTCAGGTTCTGCTGCTGAGCGAGAAGGCTTCGATTTC	88340	
Qy	1151	TTCCGGACAAATTACTTTCTCTCGCA	1181	611	TTCAAGCAGGGGCCACAGGCAACGCAAGGAAATGATTCCTTCATTCAGTGATA	670	
Db	87799	TTCCGGACAAATTACTTTCTCTCGCA	87769	88339	TTCAAGCAGGGGCCACAGGCAACGCAAGGAAATGATTCCTTCATTCAGTGATA	88280	
Qy	671	CAATACAGCAGCATAATTCAATTCTGCTTCGGACCTGGATCCTCCACCTGAAAGAT	730	Qy	671	CAATACAGCAGCATAATTCAATTCTGCTTCGGACCTGGATCCTCCACCTGAAAGAT	730
Db	88279	CAATACAGCAGCATAATTCTGCTTCGGACCTGGATCCTCCACCTGAAAGAT	88222	Db	88279	CAATACAGCAGCATAATTCTGCTTCGGACCTGGATCCTCCACCTGAAAGAT	88222
Qy	731	AAGGGAAACATTCTGCTGATCGAGCCAGGCCATGATGCCGGTAACGGTGCAT	790	Qy	731	AAGGGAAACATTCTGCTGATCGAGCCAGGCCATGATGCCGGTAACGGTGCAT	790
Db	88219	AAGGGAAACATTCTGCTGATCGAGCCAGGCCATGATGCCGGTAACGGTGCAT	88166	Db	88219	AAGGGAAACATTCTGCTGATCGAGCCAGGCCATGATGCCGGTAACGGTGCAT	88166
Qy	791	GCGTCATTATGCAATGCGGCAAGTGTGAAACCGGTACCGTTGCTCT	850	Qy	791	GCGTCATTATGCAATGCGGCAAGTGTGAAACCGGTACCGTTGCTCT	850
Db	88159	GGCTTCATTATGCAATGCGGCAAGTGTGAAACCGGTACCGTTGCTCT	88100	Db	88159	GGCTTCATTATGCAATGCGGCAAGTGTGAAACCGGTACCGTTGCTCT	88100
Qy	851	GACACCTTCGGCATCATGAGTCGCCATCATGGGTGAAATGAATGAAATCACA	910	Qy	851	GACACCTTCGGCATCATGAGTCGCCATCATGGGTGAAATGAATGAAATCACA	910
Db	88099	GACACCTTCGGCATCATGAGTCGCCATCATGGGTGAAATGAATGAAATCACA	88044	Db	88099	GACACCTTCGGCATCATGAGTCGCCATCATGGGTGAAATGAATGAAATCACA	88044
Qy	911	CAGATAATTCAAGGAAACGTTCTGGCTTAACGGTGTAGTAGGTTTGTGCAAT	970	Qy	911	CAGATAATTCAAGGAAACGTTCTGGCTTAACGGTGTAGTAGGTTTGTGCAAT	970
Db	88039	CAGATAATTCAAGGAAACGTTCTGGCTTAACGGTGTAGTAGGTTTGTGCAAT	87988	Db	88039	CAGATAATTCAAGGAAACGTTCTGGCTTAACGGTGTAGTAGGTTTGTGCAAT	87988
Qy	971	AGTGAAGGCCGCTGACGATATGACGGTCACTGCTGTATAATTCTGTCATGGCACT	1030	Qy	971	AGTGAAGGCCGCTGACGATATGACGGTCACTGCTGTATAATTCTGTCATGGCACT	1030
Db	87979	ACIGAAAGCCTGACAGCATATGACGGTCACTGCTGTATAATTCTGTCATGGCACT	87924	Db	87979	ACIGAAAGCCTGACAGCATATGACGGTCACTGCTGTATAATTCTGTCATGGCACT	87924
Qy	1031	ATGGCAGATGACCAAGATCAGGTTAAATCCCGATAATTGGTCAAGTCTGAGATGGAA	1090	Qy	1031	ATGGCAGATGACCAAGATCAGGTTAAATCCCGATAATTGGTCAAGTCTGAGATGGAA	1090
Db	87919	ATGGCAGATGACCAAGATCAGGTTAAATCCCGATAATTGGTCAAGTCTGAGATGGAA	87860	Db	87919	ATGGCAGATGACCAAGATCAGGTTAAATCCCGATAATTGGTCAAGTCTGAGATGGAA	87860
Qy	1091	AGGAAGGTGAAGGCTGTTCTGAAAGGAAATAAGTGAATCATGCCCCCTTCTGGC	1150	Qy	1091	AGGAAGGTGAAGGCTGTTCTGAAAGGAAATAAGTGAATCATGCCCCCTTCTGGC	1150
Db	87859	AGGAAGGTGAAGGCTGTTCTGAAAGGAAATAAGTGAATCATGCCCCCTTCTGGC	87800	Db	87859	AGGAAGGTGAAGGCTGTTCTGAAAGGAAATAAGTGAATCATGCCCCCTTCTGGC	87800
Qy	1151	TTCCGGAGCAATTTCATCTTTCTCTCTGAG	1181	Qy	1151	TTCCGGAGCAATTTCATCTTTCTCTCTGAG	1181
Db	87799	TTCCGGAGCAATTTCATCTTTCTCTCTGAG	87769	Db	87799	TTCCGGAGCAATTTCATCTTTCTCTCTGAG	87769
Qy	9	RESULT 9		Qy	9	RESULT 9	
Db	AF043470	5612 bp DNA		Db	AF043470	5612 bp DNA	
LOCUS	Escherichia coli plasmid pO157	ecf4 gene, partial cds; and ecf3;		LOCUS	Escherichia coli plasmid pO157	ecf4 gene, partial cds; and ecf3;	
DEFINITION	Escherichia coli pO157 ecf4 gene, partial cds; and ecf3.		DEFINITION	Escherichia coli pO157 ecf4 gene, partial cds; and ecf3.			
ECF2	AF043470		ECF2	AF043470			
ECF1	AF043470		ECF1	AF043470			
VERSION	GI:3253288		VERSION	GI:3253288			
KEYWORDS			KEYWORDS				
SOURCE			SOURCE				
ORGANISM	Escherichia coli		ORGANISM	Escherichia coli			
ESCHERICHIA COLI			ESCHERICHIA COLI				
ENTEROBACTERIAEAE			ENTEROBACTERIAEAE				
ENTEROBACTERIA			ENTEROBACTERIA				
ESCHERICHIA			ESCHERICHIA				
REFERENCE			REFERENCE				
AUTHORS	1 (bases 1 to 5612)		AUTHORS	1 (bases 1 to 5612)			
Boerlin, P., Chen, S., Colbourne, J. K., Johnson, R., De Grandis, S. and Gyles, C.			Boerlin, P., Chen, S., Colbourne, J. K., Johnson, R., De Grandis, S. and Gyles, C.				
TITLE	Evolution of enterohemorrhagic Escherichia coli hemolysin plasmids and the locus for enterocyte effacement in shiga toxin-producing E. coli		TITLE	Evolution of enterohemorrhagic Escherichia coli hemolysin plasmids and the locus for enterocyte effacement in shiga toxin-producing E. coli			
JOURNAL	Infec. Immun.		JOURNAL	Infec. Immun.			
MEDLINE	66 (6)		MEDLINE	66 (6)			
PUBLISHED	2553-2561 (1998)		PUBLISHED	2553-2561 (1998)			
REFERENCE	2 (bases 1 to 5612)		REFERENCE	2 (bases 1 to 5612)			
AUTHORS	Boerlin, P. and Gyles, C.		AUTHORS	Boerlin, P. and Gyles, C.			
Direct Submission			Direct Submission				

source 1. 14 /organism="unknown" /mol_type="unassigned" DNA

ORIGIN

Query Match 100.0%; Score 8; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 5.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCGTCAG 8
Db 11 ATCGTCAG 4

RESULT 9
BD205228 LOCUS BD205228⁸ Nucleotide sequence for detecting enterohemorrhagic Escherichia coli (EEHEC).
DEFINITION
ACCESSION BD205228
VERSION BD205228.1 GI:33014998
KEYWORDS JP 2002512813-A/18.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Prechon, D.T.M., Laure, F.C. and Thierry, D.
TITLE Nucleotide sequence for detecting enterohemorrhagic Escherichia coli (EEHEC).
PATENT: JP 2002512813-A 18 08-MAY-2002;

JOURNAL
COMMENT OS unidentified
JP 2002512813-A/18
PN 08-MAY-2002
PD 08-MAY-2002
PR 27-APR-1999 JP 2000546051
PR 28-APR-1998 FR 98/05329
PI DOMINIQUE THIERRY
PC C12N9/08, C07K14/245, C12N1/21, C12N15/09, C12Q1/68, C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
CC Nucleotide sequence for detecting enterohemorrhagic Escherichia coli
(EEHEC).
Key
FT source 1. 14
FT FT /organism='Unidentified'.
FEATURES
source 1. 14
LOCUS "unidentified"
/mol type="genomic DNA"
/db_xref="taxon:32644"
ORIGIN

Query Match 100.0%; Score 8; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 5.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCGTCAG 8
Db 11 ATCGTCAG 4

RESULT 8
BD132864/C LOCUS BD132864 Nucleic acid probes for the detection and identification of fungi.
DEFINITION Nucleic acid probes for the detection and identification of fungi.
ACCESSION BD132864
VERSION BD132864.1 GI:23227809
KEYWORDS JP 2002504817-A/5.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Sandhu, G.S. and Kline, B.C.
TITLE Nucleic acid probes for the detection and identification of fungi
JOURNAL Patent: JP 2002504817-A 5 12-FEB-2002;

COMMENT JP 2002504817-A/5
FD 12-FEB-2002
PF 04-JUN-1998 JP 1999501953
PR 06-JUN-1997 US 08/871678
P1 GURPREET S SANDHU, BRUCE C KLINE
PC C12Q1/68
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FEATURES
source 1. 14
/organism="Unidentified"
/mol type="genomic DNA"
/db_xref="taxon:32644"
ORIGIN

Query Match 100.0%; Score 8; DB 6; Length 14;
Best Local Similarity 100.0%; Pred. No. 5.1e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ATCGTCAG 8
Db 4 ATCGTCAG 11

RESULT 10
I79345/C LOCUS I79345 Sequence 5 from patent US 5107802.
DEFINITION Sequence 5 from patent US 5107802.
ACCESSION I79345
VERSION I79345.1 GI:3207635
KEYWORDS Unknown
SOURCE Unknown
ORGANISM Unknown
REFERENCE 1 (bases 1 to 14)
AUTHORS Sandhu, G.S. and Kline, B.C.
TITLE Nucleic acid probes for the detection and identification of fungi
JOURNAL Patent: US 5107802-A 5 13-JAN-1998;

Best Local Similarity 100.0%; Pred. No. 4.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 14; Conservative 0; NOS: US20040029129A1

Y 1 GGCATCGTCAGTTG 14
b 420 GGCATCGTCAGTTG 407

RESULT 2
S-10-282-122A-36930
Sequence 36930, Application US/10282122A
Publication No. US20040029129A1

GENERAL INFORMATION:

APPLICANT: Wang, Lianguu
APPLICANT: Zamudio, Carlos
APPLICANT: Malone, Cheryl
APPLICANT: Haselbeck, Robert
APPLICANT: Ohlsen, Kari
APPLICANT: Zyskind, Judith
APPLICANT: Wall, Daniel
APPLICANT: Trawick, John
APPLICANT: Carr, Grant
APPLICANT: Yamamoto, Robert
APPLICANT: Forsyth, R.
APPLICANT: Xu, H.

TITLE OF INVENTION: Identification of Essential Genes in Microorganisms

FILE REFERENCE: ELITRA_034A

CURRENT APPLICATION NUMBER: US/10/282,122A
CURRENT FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: 60/191,078
PRIOR FILING DATE: 2000-03-21

PRIOR APPLICATION NUMBER: 60/206,848
PRIOR FILING DATE: 2000-05-23

PRIOR APPLICATION NUMBER: 60/207,727
PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: 60/230,335
PRIOR FILING DATE: 2000-09-06

PRIOR APPLICATION NUMBER: 60/240,347
PRIOR FILING DATE: 2000-09-09

PRIOR APPLICATION NUMBER: 60/242,578
PRIOR FILING DATE: 2000-10-23

PRIOR APPLICATION NUMBER: 60/253,625
PRIOR FILING DATE: 2000-11-27

PRIOR APPLICATION NUMBER: 60/257,931
PRIOR FILING DATE: 2000-12-22

PRIOR APPLICATION NUMBER: 60/267,636
PRIOR FILING DATE: 2001-02-09

PRIOR APPLICATION NUMBER: 60/269,308
PRIOR FILING DATE: 2001-02-16

Remaining Prior Application data removed - See File Wrapper or PAML.

NUMBER OF SEQ ID NOS: 78614
SOFTWARE: PatentIn version 3.1
SEQ ID NO: 36930
LENGTH: 1285

Qy 1 GGCATCGTCAGTTG 14
Db 403 GGCATCGTCAGTTG 416

Query Match 100.0%; Score 14; DB 17; Length 1285;
Best Local Similarity 100.0%; Pred. No. 4.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 14; Conservative 0; NOS: US/10282122A
Organism: Salmonella Baratyphi A

RESULT 3
S-10-282-122A-40133
Sequence 40133, Application US/10282122A
Publication No. US20040029129A1

GENERAL INFORMATION:

DEFINITION		1489 bp		DNA linear		PAT 17-JUL-2003	
ACCESSION	VERSION	Nucleotide sequence for detecting enterohemorrhagic Escherichia coli (EEHC).					
SOURCE	ORGANISM	BD205211					
unclassified		BD205211		GI:33014981			
unclassified		JP 2002512813-A1.					
unclassified		unclassified					
unclassified.		1 (bases 1 to 1489)					
REFERENCE		Prechon, D.T.M., Laure, F.C. and Thierry, D.					
AUTHORS	TITLE	Nucleotide sequence for detecting enterohemorrhagic Escherichia coli (EEHC)					
JOURNAL		Patent: JP 2002512813-A 1 08-MAY-2002;					
COMMENT		Biorad Pasteur					
OS		Unidentified					
PN		JP 2002512813-A/1					
PD		JP 08-MAY-2002					
PF		JP 2000546051					
PR		27-APR-1999		JP 2000546051			
PR		28-APR-1998		FR 98/053229			
PI		DOMINIQUE THERESE MARIE PRECHON, FRANCOISE CLAUDINE LAURE, PI					
DOMINIQUE THIERRY		DOMINIQUE THIERRY					
PC		PC 'C12N9/08, C07K14/245, C12N1/21, C12N15/09, C12N1/68, C12N15/00 CC					
Strandedness: Double;							
CC		Topology: Linear;					
CC		Nucleotide sequence for detecting enterohemorrhagic CC					
Escherichia coli		(EEHC).					
CC		Key		Location/Qualifiers			
PH		source		1..1489			
FT		/organism='Unidentified'.					
FEATURES		Source		Location/Qualifiers			
Qy		1..1489		1..1489			
Db		/organism="Unidentified"		/organism="Unidentified"			
/mol_type="genomic DNA"		/mol_type="genomic DNA"					
/db_xref="taxon:32644"							
ORIGIN							
Query Match		100.0%;		Score 16;		DB 6;	
Best Local Similarity		100.0%;		Length 1489;			
Matches		16;		Prod. No. 6.2e+02;			
Matches		16;		Conservative		Mismatches 0;	
DEFINITION		Sequence 1		Indels 0;		Gaps 0	
ACCESSION		from Patent AX011297					
VERSION		AX011297		GI:9997847			
KEYWORDS		Escherichia coli					
SOURCE		Escherichia coli					
ORGANISM		Bacterium; Proteobacteria; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae; Escherichia.					
REFERENCE		1. Thierry, D., Prechon, D.T. and Laure, F.C.					
AUTHORS		Nucleotide sequences for detecting enterohemorrhagic Escherichia					
TITLE		coli (EEHC).					
PATENT		Patent: WO 995908-A 1 04-NOV-1999;					
JOURNAL		THIERRY DOMINIQUE (FR); FRECHON DOMINIQUE THERESE MARI (FR); LAURE, FRANCOISE CLAUDINE (FR); PASTEUR SANOTI DIAGNOSTICS (FR)					
FEATURES		Location/Qualifiers					
Qy		1..1489		/organism="Escherichia coli"			
Db		/mol_type="unassigned DNA"		/db_xref="taxon:562"			
ORIGIN							
Query Match		100.0%;		Score 16;		DB 6;	
Best Local Similarity		100.0%;		Length 1489;			
Matches		16;		Prod. No. 6.2e+02;			
DEFINITION		Sequence 1		Mismatches 0;			
ACCESSION		from Patent AX011297		Indels 0;			
VERSION		AX011297		Gaps 0			
KEYWORDS		Escherichia coli					
SOURCE		Escherichia coli					
ORGANISM		Bacterium; Proteobacteria; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae; Escherichia.					
REFERENCE		1. Thierry, D., Prechon, D.T. and Laure, F.C.					
AUTHORS		Nucleotide sequences for detecting enterohemorrhagic Escherichia					
TITLE		coli (EEHC).					
PATENT		Patent: WO 995908-A 1 04-NOV-1999;					
JOURNAL		THIERRY DOMINIQUE (FR); FRECHON DOMINIQUE THERESE MARI (FR); LAURE, FRANCOISE CLAUDINE (FR); PASTEUR SANOTI DIAGNOSTICS (FR)					
FEATURES		Location/Qualifiers					
Qy		1..1489		/organism="Escherichia coli"			
Db		/mol_type="unassigned DNA"		/db_xref="taxon:562"			
ORIGIN							

/evidence=experimental]

ORIGIN GenBank Accession Number AE016860"

Query Match 100.0%; Score 16; DB 1; Length 1517;

Best Local Similarity 100.0%; Pred. No. 6.1e+0; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 0;

Qy 1 CGGATCGTCAGTGC 16

Db 763 CGGATCGTCAGTGC 748

/note="repA"

/locus tag="PMA4326B01"

/gene="repA"

/product="repA"

/transl_table=11

/protein="single-stranded binding protein"

/note="similar to *Escherichia coli* O157:H7 EDL933 unknownprotein encoded by *Cryptic prophage CP933P* encoded by

GenBank Accession Number AB05461; possible

post-segregational killing system"

/codon_start=1

/product="stability determinant"

/transl_table=11

/protein id="AT35170_1"

/db_xref="GI:47525157"

/translation="MEKIMIDRSPIVSFETEELEANTYAWLRKVEASLADSRPAI

PHDEVERMAMERLARLRRRAS"

2016 . 2016

/note="similar to *Escherichia coli* O157:H7 hypothetical

protein encoded by GenBank Accession Number AP002557;

similar to plasmid stabilization system protein

(PFAM05016); possible post segregational killing system"

/codon_start=1

/product="stability determinant"

/transl_table=11

/protein id="AT35171_1"

/db_xref="GI:47525158"

/translation="MLPPIWLESADDNLIAAELIYEYIGRLDIAAERLWORLRGIVLPLS

BHPVYIAISDRVPGMREIVTAHPNVLVPYRTSIRLEVNTVHARQBYPTQGLA"

2016 . 2016

/note="similar to *Escherichia coli* O157:H7 hypothetical

protein encoded by GenBank Accession Number AP002557;

similar to plasmid stabilization system protein

(PFAM05016); possible post segregational killing system"

/codon_start=1

/product="stability determinant"

/transl_table=11

/protein id="AT35172_1"

/db_xref="GI:47525159"

/translation="MVMVSLQMDLMDAHLNSLEAKVAPLGSITWMSKARILUNKGKPVV

TVSSSERLRLDKMKAEEAKKATKATPSPLEMSEDDTGAPYLLEQTLLQCVIA

EQLGAIAPPDEKWLARVIPSRLSOLQSKTGLH"

3001 . 5096

/note="inactive"

/transl_table=11

/product="hypothetical protein"

/protein id="AT35172_1"

/db_xref="GI:47525159"

/translation="TVSSSERLRLDKMKAEEAKKATKATPSPLEMSEDDTGAPYLLEQTLLQCVIA

EQLGAIAPPDEKWLARVIPSRLSOLQSKTGLH"

3181 . 4741

/note="similar to *Pseudomonas syringae* pv. *maculicola* M6

plasmid PDC3000A unknown encoded by GenBank Accession Number

AP359557; insertion caused disruption and frameshift in

the ORF; left and right borders still intact"

/pseudo

complement (5094 . 5256)

/locus tag="MPB01"

/note="similar to *Pseudomonas syringae* pv. *tomato* str.

DC3000 ISPBBy transposase encoded by GenBank Accession

Number AE016867"

/pseudo

5391 . 6809

/locus tag="PMA4326B06"

5391 . 6809

gene

/product="repA"

/locus tag="PMA4326B01"

/note="similar to *Pseudomonas syringae* pv. *tomato* DC3000

plasmid PDC3000A replication protein RepA encoded by

GenBank Accession Number AB016855"

/codon_start=1

/product="replication protein"

/protein id="AT35168_1"

/db_xref="GI:47525155"

/translation="MNNHDNALSLSLAASHTANADPLASSTHLPPARFFEDGTALNRLL

LEAPYMARCSDDKTAATVRRPEYALRYPYQMVNRPMVSNLVEFDLHANALMDAGL

PAPLNLMVRNPKGSQSLFYAVPSVCTENAKRPLDADVDHGG

PVAKTGTGHPWETTEPHSHYVYELGELASAVELTVEWATSPKLDVSHSRHCLLFEOL

RYFAYSVNREERELGSEFSEMRSLDAYNNHNSNLKQGEFENLPLSSTRATVSYGRW

TWDRTGDRRCHGANOQDSSLSLTERQSLALARTHELKATBSKIRACRQDQDG

KALVRSATIAQVASTVARYAHILTEVTKPATVSVLKAVPAANDRAGPGECKAVK

PKKQGLADHDQGAPYGVHQ1SAVPEGPQAGEFLLTIEHEDGS"

1451 . 1744

/note="ssb"

/locus tag="PMA4326B02"

/note="similar to *Pseudomonas syringae* pv. *tomato* DC3000

plasmid PDC3000A DNA-binding protein HU family encoded by

/codon_start=1

/product="ssb"

/locus tag="PMA4326B02"

/note="similar to *Pseudomonas syringae* pv. *tomato* str.

DC3000 ISPBBy transposase encoded by GenBank Accession

Number AE016867"

/pseudo

5391 . 6809

/locus tag="PMA4326B06"

5391 . 6809

gene

/product="ssb"

/locus tag="PMA4326B01"

/note="similar to *Pseudomonas syringae* pv. *maculicola* M6

plasmid PDC3000A unknown encoded by GenBank Accession

Number AP359557; insertion caused disruption and frameshift in

the ORF; left and right borders still intact"

/pseudo

5391 . 6809

/locus tag="PMA4326B06"

5391 . 6809

gene

/product="ssb"

/locus tag="PMA4326B01"

/note="similar to *Pseudomonas syringae* pv. *maculicola* M6

plasmid PDC3000A unknown encoded by GenBank Accession

Number AP359557; insertion caused disruption and frameshift in

the ORF; left and right borders still intact"

/pseudo

5391 . 6809

/locus tag="PMA4326B06"

5391 . 6809

gene

/product="ssb"

/locus tag="PMA4326B01"

/note="similar to *Pseudomonas syringae* pv. *maculicola* M6

plasmid PDC3000A unknown encoded by GenBank Accession

Number AP359557; insertion caused disruption and frameshift in

the ORF; left and right borders still intact"

/pseudo

5391 . 6809

/locus tag="PMA4326B06"

5391 . 6809

gene

/product="ssb"

/locus tag="PMA4326B01"

/note="similar to *Pseudomonas syringae* pv. *maculicola* M6

plasmid PDC3000A unknown encoded by GenBank Accession

Number AP359557; insertion caused disruption and frameshift in

the ORF; left and right borders still intact"

/pseudo

5391 . 6809

/locus tag="PMA4326B06"

5391 . 6809

gene

/codon_start=1
 /transl_table=11
 /product="replication initiation protein"
 /protein_id="AAC70076_1"
 /db_xref="GI:3822122"
 /translation="MIDLQQTYYTROVKNPVPFTPREGAGTILKECEKLMKEAVGFTSR
 LPTFAIHYAHARSKGLRERMRPPTLRLRQYDPLIGCYPTDITCPALFAALDV
 SEDAAJARRSERVEWENLIRKQGDLTGMDDLLIAKWRFVRERPSYQPELKSIGK
 RARARRDAGRERQDITVLVKRQTRTEISGRFTANREAVRKREVERVKERNILSRNRN
 YSLRATGSP"
 3847. 4095
 misc_feature
 /standard_name="CIS"
 /note="88 pct identical to locus ECC15 accession X12587,
 required for cis-activation of oriR by the replication
 initiation protein"
 misc_feature
 4072. 4080
 /note="dnAA site; 100 pct identical (0 gaps) to locus
 BCR1REP at (1682 . 1690) accession X02302"
 4084. 4232
 /standard_name="oriR"
 /note="89 pct identical to oriR (1094 . 1242); minimum
 segment for replication of E. coli IncFII plasmid NR1
 BCRREP1 X11776"
 /direction=right
 4169. 4197
 /note="predicted sigma 70 promoter; score of 56%"
 gene
 4259. 4453
 /gene="L7009"
 4259. 4453
 /gene="L7009"
 /note="95 pct identical to (0 gaps) 64 residues of a 128
 aa protein REP4 locus ECRS1 accession V00351"
 /codon_start=1
 Query Match
 Best Local Similarity 100.0%; Score 26; DB 1; Length 92077;
 Matches 26; Conservative 0; Pred. No. 0.19; Gaps 0;
 gene
 1 AAGGGTTCCAAGCGGCACTGACCA 26
 ||||| ||||| ||||| ||||| |||||
 Db 7262 AAGGGTTCCAAGCGGCACTGACCA 7237
 /codon_start=1
 RESULT 6
 AX191727/c
 LOCUS AX191727
 DEFINITION Sequence 9 from Patent WO149775.
 VERSION GI:15209896
 KEYWORDS
 SOURCE
 ORGANISM
 Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
 Enterobacteriaceae; Escherichia.
 1
 Iversen, P.L.
 Autisen, S.
 Title: WO 0149775-A 9 12-JUL-2001;
 Patent: WO 0149775-A 9 12-JUL-2001;
 Avi Biopharma, Inc. (US)
 Location/Qualifiers
 1. 92077
 /organism="Escherichia coli"
 /mol_type="unassigned DNA"
 /db_xref="taxon:562"
 Query Match
 Best Local Similarity 100.0%; Score 26; DB 6; Length 92077;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 gene
 1 AAGGGTTCCAAGCGGCACTGACCA 26
 ||||| ||||| ||||| ||||| |||||
 ORIGIN
 1. 92077
 /organism="Escherichia coli"
 /mol_type="unassigned DNA"
 /db_xref="taxon:562"
 Query Match
 Best Local Similarity 100.0%; Score 26; DB 6; Length 92077;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 gene
 1 AAGGGTTCCAAGCGGCACTGACCA 26
 ||||| ||||| ||||| ||||| |||||
 /organism="Escherichia coli"
 /mol_type="unassigned DNA"
 /db_xref="taxon:562"
 /gene="tcpC"
 /gene="tcpC"
 /gene="tcpC"
 /gene="tcpC"

```

Query Match 100.0%; Score 26; DB 1; Length 92077;
Best Local Similarity 100.0%; Pred. No. 0.12; Mismatches 0; Gaps 0;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 1 TAAGGGTTCCAAGGGCACTGAGC 26
b 7263 TAAGGGTTCCAAGGGCACTGAGC 7238

RESULT 6
X191727/c AX191727 92077 bp DNA linear PAT 15-AUG-2001
DEFINITION Sequence 9 from Patent WO0149775.
ACCESSION AX191727
VERSION 1 GI:15209896
KEYWORDS
SOURCE Escherichia coli
ORGANISM Escherichia coli
BACTERIA Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
ENTEROBACTERIAE; Escherichia.
1 Iversen, P.L.
AUTHORS Antisense antibacterial cell division composition and method
TITLE Patent: WO 0149775 A 9 12-JUL-2001;
JOURNAL Avi Biopharma, Inc. (US)
FEATURES Location/Qualifiers
1. 92077 /organism="Escherichia coli"
/ mol type="unassigned DNA"
/ db_xref="taxon:562"
REFERENCE
SOURCE
ORIGIN
Query Match 100.0%; Score 26; DB 6; Length 92077;
Best Local Similarity 100.0%; Pred. No. 0.12; Mismatches 0; Gaps 0;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 TAAGGGTTCCAAGGGCACTGAGC 26

```

Db	7263	TAAGGGTTCCAGCCAACTGACG	7238
RESULT	7		
AB011549/c	AB011549	Escherichia coli plasmid p0157	92721 bp
LOCUS	AB011549	Escherichia coli	DNA
DEFINITION	AB011549	GI:14589740	
ACCESSION	AB011549	ToxR-regulated lipoprotein; tagA.	
VERSION	AB011549.2		
KEYWORDS			
SOURCE			
Escherichia coli			
ORGANISM			
Escherichia coli			
Bacteria; Proteobacteria; Gammaproteobacteria; Escherichia.			
1 (sites)			
REFERENCE			
AUTHORS	Makino, K., Ishii, K., Yasunaga, T., Yutsubo, H. C., Kubota, Y., Yamaichi, Honda, T., Han, C. G., Ohtsubo, E., K. and Shinagawa, H.		
TITLE	Complete nucleotide sequences of enterohemorrhagic Escherichia coli outbreak		
JOURNAL	DNA Res.	5 (1), 1-9 (1998)	
MEDLINE	98290340		
PUBMED	9628576		
REFERENCE	2 (bases 1 to 92721)		
AUTHORS	Makino, K.		
TITLE	Direct Submission		
JOURNAL	Submitted (24-FEB-1998)		
COMMENT	Kozo Makino		
FEATURES	Microbial Diseases, Osaka University		
	Yamadaoka, 3-1, Suita, Osaka 562.		
	(B-mail: makino@bmsn01.biken.osaka.ac.jp)		
	Fax: 81-6-879-8320)		
	On Apr 20, 1999 this sequence was		
	Location/Qualifiers		

```

Query Match 100.0%; Score 26; DB 1; Length 92077;
Best Local Similarity 100.0%; Pred. No. 0.12; Mismatches 0; Gaps 0;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Y 1 TAAGGGTTCCAAGGGCACTGAGC 26
b 7263 TAAGGGTTCCAAGGGCACTGAGC 7238

RESULT 6
X191727/c AX191727 92077 bp DNA linear PAT 15-AUG-2001
DEFINITION Sequence 9 from Patent WO0149775.
ACCESSION AX191727
VERSION 1 GI:15209896
KEYWORDS
SOURCE Escherichia coli
ORGANISM Escherichia coli
BACTERIA Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
ENTEROBACTERIAE; Escherichia.
1 Iversen, P.L.
AUTHORS Antisense antibacterial cell division composition and method
TITLE Patent: WO 0149775 A 9-12-JUL-2001;
JOURNAL Avi Biopharma, Inc. (US)
FEATURES Location/Qualifiers
1. 92077 /organism="Escherichia coli"
/ mol type="unassigned DNA"
/ db_xref="taxon:562"
FEATURES Source
ORIGIN
Query Match 100.0%; Score 26; DB 6; Length 92077;
Best Local Similarity 100.0%; Pred. No. 0.12; Mismatches 0; Gaps 0;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
b 1 TAAGGGTTCCAAGGGCACTGAGC 26

```

Db	7263	TAAGGGGTTCCAGGCGCAACTGACG	7238
RESULT 7			
LOCUS	AB011549	92721 bp	DNA circular BCT 27-APR-1999
DEFINITION	Escherichia coli plasmid pO157	DNA	complete sequence.
ACCESSION	AB011549		
VERSION	AB011549.2	GI:4589740	
KEYWORDS	ToxR-regulated lipoprotein; tagA.		
SOURCE	Escherichia coli		
ORGANISM	Escherichia coli		
BACTERIA	Proteobacteria; Gammaproteobacteria; Enterobacteriales;		
ENTEROBACTERIAEAE	Escherichia.		
1 (Bites)			
MAKINO, K., ISHII, K., YASUNAGA, T., HATTORI, M., YOKOYAMA, K.,			
YUTSUO, H. C., KUBOTA, Y., YAMAIUCHI, Y., IIDA, T., YAMAMOTO, K., KUHARA, S.,			
HONDA, T., HAN, C. G., OHTSUBO, E., KASAMATSU, M., HAYASHI, T.,			
AND SHINAGAWA, H.			
TITLE	Complete nucleotide sequences of 93-kb and 3.3-kb plasmids of an enterohemorrhagic Escherichia coli O157:H7 derived from Sakai outbreak	5 (1), 1-9 (1998)	
JOURNAL	DNA Res.		
MEDLINE	98290540		
PUBMED	9628576		
REFERENCE	2 (bases 1 to 92721)		
AUTHORS	Makino, K.		
TITLE	Direct Submission		
JOURNAL	Submitted (24-FEB-1998) Kozo Makino, Research Institute for Microbial Diseases, Osaka University, Molecular Microbiology; Yamadaoka, 3-1, Suita, Osaka 562, Japan		
COMMENT	(E-mail: makino@bbs01.biken.osaka-u.ac.jp, Tel: 01-6-879-8318, Fax: 01-6-879-8320)		
FEATURES	On Apr 20, 1999 this sequence version replaced 91:33336997.		
LOCATOR/Qualifiers			


```

TAQIAVQASITGHVLVLISTLHTNSAAGALSLQDMGIPPFPLSTLLAQLRVLTC
PRCROPCCVTELAMDMDIPETTIWOPACGOCHCSFTGHGRTGTHLILLDDRTTA
IYQGEGELGTRLAGSRYLTIRGDRQKVLAGETSWEETVRVTESRLQSEE"
6939. . 8162
/gene= "etpF"
6939. . 8162
/gene= "etpF"
/codon_start=1
/transl_table=11
/product="Type II secretion pathway related protein"
/protein_id="BA31761.1"
/db_xref="GI: 3337002"
/transl_table="WALFYHQASDTHGRKSGILEADSARHAROLLEQDQALIPVRLDE
KQVHKHSRSILRPRPGQSSAELALLTROLATVAAASPLERBALDALLVQKQSPRQ
RNVIAVTRVTRVTEGHISAAAGMMPOTERIYCAMVAGGETSGRDLVYLSRLADYQ
RQIMRNRLQQLLPCVTLVAVGVTAAITAVPKVKEQFTHMKOTPLPLSTRVLMGA
AEVSCTWGPVLLAAGGIAAGRMLHQPSORLAFLHLLRPLPVGCRISRLGNTA
RTLSINASAPVLLQAMKISQDVLNDWHRQHQLNAAELREGVSLQALETQSTLFP
MMRTEIASGENSGEGLDMSMLERAAADNODREFSTOMQALGLFEPFLVVGAGVVLFV
A10QPLQLQNNNNNN"
8193. . 8162
/gene= "etpG"
8193. . 8162
/gene= "etpG"
/codon_start=1
/transl_table=11
/product="Type II secretion pathway related protein"
/protein_id="BA31762.1"
/db_xref="GI: 3337003"
/transl_table="MREKQHQQRGFTPLILQMVIVLVLVAGSLWVNPMLMGNDKADQKV
MSDLVALESTUDMYLDNMRNRPTEPTEOGLRALVSKPTVQQPBPRTYRQDGTTRLPPQDPQW
GGDYQLINPGQYSQSDIDIFSPGPQGVNTEDDIGNWTLGNAQP"
8624. . 9178
/gene= "etpH"
8624. . 9178
/gene= "etpH"
/codon_start=1
/transl_table=11
/product="Type II secretion pathway related protein"
/protein_id="BA31763.1"
/db_xref="GI: 3337004"
/transl_table="MSQURGFTLILMILLINGITAGLIVMSFQDPAQNHILQQQRERL
QAOQDLYALDRSDQODGLIMGIQVRDFGKFKVYLQRGTABSPPLAEGDIDWQGYWQWTW
OPRRAAMGKGKLPDDPVBLQVLRGQLMQMSHDDGAEPSDILLLPGGEVTPFLRFLFQVG
BEAVVGGVQVDENGGLMLTFLFEGEVSL"
9193. . 9540
/gene= "etpI"
9193. . 9540
/gene= "etpI"
/codon_start=1
/transl_table=11
/product="Type II secretion pathway related protein"
/protein_id="BA31764.1"
/db_xref="GI: 3337005"
/transl_table="MVTIIEVIVVALVVFALAGNAMQASQOAGIGMNEEKYLAGIA
DNOMVQQLQBLKTWPENGWERTISFAGTEWYLWRGGDDSDVQPRSLEVEVRRTKDEST
SALVLSRSVVER"
9537. . 10136
/gene= "etpJ"
9537. . 10136
/gene= "etpJ"
/codon_start=1
/transl_table=11
/product="Type II secretion pathway related protein"
/protein_id="BA31765.1"
/db_xref="GI: 3337006"
/transl_table="MSQORRQVKGFTLLENLLAVALFAAALISAFQVLOGQIRAHLSID
KVRLAEIORGISQMERLDTQMPRHSQNEGHLAAAPHLKSDDWGISETNSWLNPE
AGRLVQDQYVRLRQKLERLSFVDFBPGVSPVDFVRLGVHAFRLRFVNGD"
10133. . 11110
/gene= "etpK"
10133. . 11110
/gene= "etpK"

```

LOCUS	AFO74613	92077 bp	DNA	circular BCT 04-NOV-1998
DEFINITION	Escherichia coli O157:H7 Plasmid pO157, complete sequence.			
VERSION	AFO74613			
AUTHORS	Blattner, F.R.			
ORGANISM	Escherichia coli O157:H7			
SOURCE	Escherichia coli O157:H7			
REMARKS	Bacteria: Proteobacteria: Gammaproteobacteria: Enterobacteriales; Enterobacteriaceae; Escherichia.			
REFERENCE	1 (bases 1 to 92077)			
AUTHORS	Burland, V., Shao, Y., Perna, N.T., Plunkett, G., Sofia, H.J. and Blattner, F.R.			
JOURNAL	Plasmid			
MEDLINE	9831744			
pubmed	9722640			
REFERENCE	2 (bases 1 to 92077)			
AUTHORS	Burland, V., Shao, Y., Perna, N.T., Plunkett, G., III, Sofia, H.J. and Blattner, F.R.			
JOURNAL	Direct Submission			
MEDLINE	9831744			
pubmed	9722640			
TITLE	Submitted (25-JUN-1998) Genetics, University of Wisconsin, 445 Henry Mall, Madison, WI 53706, USA			
JOURNAL	Genetics			
SEQUENCES	Location/Qualifiers			
	1..92077			
	/organism="Escherichia coli O157:H7"			
	/mol_type="genomic DNA"			
	/strain="SD1933"			
	/serotype="O157:H7"			
	/db_xref="taxon:83334"			
	/1ab_host=Escherichia coli C600"			
	/plasmid="pO157"			
	1..561			
	/gen="finO"			
	/note="synonym: L7001"			
	1..561			
	/gen="finO"			
	/note="97 pct identical amino acid sequence and equal length to F101_ECOLI SW: P22707"			
	/codon_start=1			
	/transl_table=11			
	/product="fertility inhibition protein (conjugual transfer repressor)"			
	/protein_id="AAC70069_1"			
	/db_xref="GI:3822115"			
	/translation="MAEQQRPVVLTQKRTGEETPVRSRKTIINVTTPPKWVYKOKLAVLIEDVQKNIPLSKHKLRAILKTRTSESYLCAKAGCRYTEGVYTHEISQEEAYAARLQDKRQRNIKELQAVLDEK"			
	653..681			
	/note="predicted sigma 70 promoter; score of 52%"			
	698..949			
	/gene="L70002"			
	/transl_table=11			
	/product="unknown"			
	/protein_id="AAC70070_1"			
	/db_xref="GI:3822116"			
	/note="54 pct identical (1 gap) to 23 residues of an approx. 269 aa protein EXOK_RHIME SW: P33393"			
	/codon_start=1			
	/transl_table=11			
	1025..1052			
	/note="predicted sigma 70 promoter; score of 62%"			
	1151..1612			
	/gene="L7003"			
	/transl_table=11			
	1151..1612			
	/gene="L7003"			
	/transl_table=11			
	1151..1612			
	/note="98 pct identical and equal length to YFI3_ECOLI SW: Q93442"			
	/codon_start=1			
PROMOTER				
gene				
CDS				
PROMOTER				
gene				
CDS				

